MetaCap

Olema Oncology Inc. (OLMA)

NASDAQ: OLMAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

7.02-0.13 (-1.82%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

OLMA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$615.00M
EPS (TTM)
-$2.40
52-week range
6.24 – 36.26
Day range
6.88 – 7.35
Volume / Avg
1.26M / 1.27M
Beta
—

52-week range

$6.24$36.26

OLMA stock today

On Nov 20, OLMA ended the session at $7.02, shedding $0.13 (1.82%), versus the S&P 500's 3.70% decline. Shares are 80.6% below their 52-week high of $36.26, set on Dec 16, 2025 and 12.6% above the 52-week low of $6.24, near the bottom of the past year's range. OLMA is down 71.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 69.7%.

Olema Oncology has posted a net loss over the last twelve months (EPS of -$2.40), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Olema Oncology

Company profile

Olema Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for breast cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Sean P. Bohen M.D., Ph.D.
Headquarters
South San Francisco, CA
Employees
131
IPO year
2020
Website
olema.com

Financial highlights

Full financials

Olema Oncology reported a net loss of $162.5 million, compared with a loss of $129.5 million a year earlier. Diluted earnings per share came in at -$1.87.

Olema Oncology annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-162.45M$-129.47M$-96.66M$-104.79M$-71.10M
EPS (diluted)$-1.87$-2.20$-2.14$-2.62$-1.80

Analyst forecast

Forecast

Consensus (12 analysts)

strong_buy

Avg. price target

$35.50+405.70%

  • Strong buy 2
  • Buy 9
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $13.00High $59.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.73 vs $-0.60
Surprise
-21.67%

OLMA news

All OLMA news

Olema Oncology peers

Health Care sector
OLMA peer companies
CompanyPrice% ChgMarket capCompare
KURAKura Oncology Inc.6.91-5.99%$634.88Mvs OLMA
JANXJanux Therapeutics Inc.10.08-2.04%$616.73Mvs OLMA
ABUSArbutus Biopharma Corporation4.02-1.23%$616.24Mvs OLMA
SGMTSagimet Biosciences Inc. Series A9.08-5.61%$648.02Mvs OLMA
ANNXAnnexon Inc.3.10-9.09%$591.37Mvs OLMA
NVCTNuvectis Pharma Inc.19.39-2.27%$666.80Mvs OLMA
IMMXImmix Biopharma Inc.6.96-1.14%$583.33Mvs OLMA
APMDApnimed Inc.16.09-6.70%$669.84Mvs OLMA

Indexes, lists and sector

Olema Oncology stock FAQ

What is Olema Oncology's stock price today?

OLMA last traded at $7.02 as of Nov 20, 4:00 PM EST, down 1.82% on the day. Prices are delayed at least 15 minutes.

Who is Olema Oncology's CEO?

Dr. Sean P. Bohen M.D., Ph.D. is the chief executive officer of Olema Oncology Inc., which has about 131 employees.

What is the OLMA 52-week high?

The 52-week high for OLMA is $36.26 and the 52-week low is $6.24. The stock is currently 80.6% below its high.

Compare OLMA